Related Experiment Video
Updated: Aug 13, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
Published on: July 14, 2021
Predictors of adverse diastolic remodeling in non-diabetic patients presenting with ST-elevation myocardial
Lawien Al Ali1, Hilde E Groot2, Solmaz Assa2
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, the Netherlands. l.al.ali@umcg.nl.
Insights
Female gender, multivessel disease, and microvascular damage predict diastolic remodeling after ST-elevation myocardial infarction (STEMI). These factors, along with age and hypertension, influence diastolic function post-STEMI.
Area of Science:
- Cardiology
- Cardiac Imaging
- Myocardial Infarction Research
Background:
- Adverse systolic remodeling post-ST-elevation myocardial infarction (STEMI) is linked to poor outcomes.
- Diastolic remodeling following STEMI is less understood.
- Identifying predictors of diastolic remodeling is crucial for patient management.
Purpose of the Study:
- To identify factors associated with diastolic remodeling after STEMI.
- To investigate clinical, angiographic, and biomarker predictors.
- To understand the progression of diastolic dysfunction post-myocardial infarction.
Main Methods:
- Echocardiography in 267 non-diabetic STEMI patients (GIPS-III trial).
- Assessed diastolic remodeling using E/e' changes from hospitalization to 4-month follow-up.
- Multivariable regression models adjusted for age and sex.
Main Results:
- Female gender, multivessel disease, and higher glucose predicted higher E/e' at 4 months.
- Lower myocardial blush grade, AST, and NT-proBNP predicted increased E/e' over time.
- Older age and hypertension predicted worse pre-existing diastolic function.
Conclusions:
- Female gender, multivessel coronary artery disease, and microvascular damage are key predictors of adverse diastolic remodeling post-STEMI.
- Pre-STEMI factors like age and hypertension may worsen baseline diastolic function.
- Understanding these predictors can guide therapeutic strategies for post-STEMI patients.
Background:
Adverse systolic remodeling after ST-elevation myocardial infarction (STEMI) is associated with poor clinical outcomes. However, little is known about diastolic remodeling. The purpose of this study was to identify the factors leading to diastolic remodeling.
Methods:
Echocardiography was performed during hospitalization and at 4 months follow-up in 267 non-diabetic STEMI patients from the GIPS-III trial. As parameters of diastolic remodeling we used (1.) the E/e' at 4 months adjusted for the E/e' at hospitalization and (2.) the change in E/e' between hospitalization and 4 months. Multivariable regression models correcting for age and sex were constructed to identify possible association of clinical and angiographic variables as well as biomarkers with diastolic remodeling.
Results:
Older age, female gender, hypertension, multi vessel disease, higher glucose and higher peak CK were independent predictors of higher E/e' at 4 months in a multivariable model (R2:0.20). After adjustment for E/e' during hospitalization only female gender, multivessel disease and higher glucose remained predictors of E/e' at four months (R2:0.40). Lower myocardial blush grade, AST and NT-proBNP were independent predictors of a higher increase of E/e' between hospitalization and at 4 months in a multivariable model (R2:0.08).
Conclusions:
Our data supports the hypothesis that female gender, multivessel coronary artery disease, and microvascular damage are important predictors of adverse diastolic remodeling after STEMI. In addition, our data suggests that older age and hypertension prior to STEMI may have contributed to worse pre-existing diastolic function.
Trial Registration:
NIH, NCT01217307. Prospectively registered on October 8th 2010, https://clinicaltrials.gov/ct2/show/NCT01217307 .
Related Concept Videos
Heart Failure II: Pathophysiology
Coronary Artery Disease I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy

